Log in
OTCMKTS:BTGGF

BTG Stock Forecast, Price & News

$10.05
0.00 (0.00 %)
(As of 08/21/2019)
Add
Compare
Today's Range
$10.05
Now: $10.05
$10.05
50-Day Range
$10.05
MA: $10.05
$10.05
52-Week Range
$6.69
Now: $10.05
$11.06
VolumeN/A
Average Volume16,006 shs
Market Capitalization$3.88 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.26
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of crotalid snake envenomations; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company also manufactures and commercializes therapeutic ultrasound devices, and roxwood systems, as well as develops venous thrombus management devices. The company was formerly known as British Technology Group International plc and changed its name to BTG plc in March 1995. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.
Read More
BTG logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:BTGGF
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A
Employees1,631

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$3.88 billion
Next Earnings DateN/A
OptionableNot Optionable
$10.05
0.00 (0.00 %)
(As of 08/21/2019)
30 days | 90 days | 365 days | Advanced Chart

Receive BTGGF News and Ratings via Email

Sign-up to receive the latest news and ratings for BTGGF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BTG (OTCMKTS:BTGGF) Frequently Asked Questions

How has BTG's stock been impacted by COVID-19?

BTG's stock was trading at $10.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BTGGF stock has increased by 0.0% and is now trading at $10.05.
View which stocks have been most impacted by COVID-19
.

Who are some of BTG's key competitors?

Who are BTG's key executives?

BTG's management team includes the following people:
  • Dr. Louise Makin MA, Ph.D.(Cantab), MBA, DBE, CEO & Exec. Director (Age 58)
  • Mr. Duncan Kennedy A.C.A., B.Sc., CFO & Director
  • Dr. Peter Stratford, Chief Technical Officer & Head of Innovation (Age 52)
  • Mr. Andy Burrows, VP of Corp. & Investor Relations
  • Dr. Paul Mussenden, Gen. Counsel, Head of Strategic Affairs & Company Sec.

What is BTG's stock symbol?

BTG trades on the OTCMKTS under the ticker symbol "BTGGF."

How do I buy shares of BTG?

Shares of BTGGF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BTG's stock price today?

One share of BTGGF stock can currently be purchased for approximately $10.05.

How big of a company is BTG?

BTG has a market capitalization of $3.88 billion. BTG employs 1,631 workers across the globe.

This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.